CCX140-B is a novel, oral and selective chemokine receptor CCR2 antagonist. CCX140 was previously evaluated in a phase-II placebo-controlled, clinical trial in patients with diabetic nephropathy. CCX140 treatment in these patients resulted in a statistically significant reduction in proteinuria.

纯度：≥98%

CAS：1100318-47-5